Apricus Biosciences (APRI) Appoints Sequenom (SQNM) CFO Maier to Board
Tweet Send to a Friend
Up)
Apricus Biosciences, Inc. (Nasdaq: APRI) announced that Paul V. Maier, Chief Financial Officer of Sequenom, Inc. (Nasdaq: SQNM) has been appointed to the Company's Board of Directors, effective June 1, 2012.
Prior to joining Sequenom, Mr. Maier served as Senior Vice President and Chief Financial Officer of Ligand Pharmaceuticals, Inc. from 1992 until 2007, where he helped build Ligand from a venture stage company to a commercial, integrated biopharmaceutical organization. Prior to joining Ligand, he spent six years in various management and finance positions at ICN Pharmaceuticals. Mr. Maier received his M.B.A. from Harvard Business School and a B.S. from Pennsylvania State University.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Prior to joining Sequenom, Mr. Maier served as Senior Vice President and Chief Financial Officer of Ligand Pharmaceuticals, Inc. from 1992 until 2007, where he helped build Ligand from a venture stage company to a commercial, integrated biopharmaceutical organization. Prior to joining Ligand, he spent six years in various management and finance positions at ICN Pharmaceuticals. Mr. Maier received his M.B.A. from Harvard Business School and a B.S. from Pennsylvania State University.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Men's Wearhouse (MW) Terminates George Zimmer; Postpones Annual Meeting
- Owens Corning (OC) Elects Chiquita's (CQB) Lonergan to Board
- Revlon (REV) CFO Berns Resigns
Create E-mail Alert Related Categories
Management Changes
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
